Hepatitis C News

As governments across the nation focus on the opioid epidemic and the prevention of overdoses, the leading infectious disease organizations issued statements urging Congress to provide $100 million for the CDC’s Viral Hepatitis programs to prevent further outbreaks of hepatitis and HIV due to injection drug use.

Combining the efforts of public health and family practices were effective in more patients receiving hepatitis tests, but did not result in more chronic hepatitis C diagnoses, according to findings published in the Annals of Family Medicine.

Since the introduction of direct-acting antivirals, more patients with hepatitis C are achieving sustained virologic response than ever before. Even patients who failed previous interferon or DAA therapy have the opportunity for secondary treatment with newly developed drugs.

Sovaldi with ribavirin was safe and effective among a cohort of Japanese patients with hepatitis C genotype 2, according to a recently published study. However, renal dysfunction correlated significantly with a lower rate of sustained virologic response.

BETHESDA, Maryland — In this exclusive video from the AASLD Industry Colloquium 2018, Kris V. Kowdley, MD, FAASLD, from Swedish Medical Center in Seattle, Washington, discusses the topics covered at the meeting and the opportunities for representatives of the industry, academia and regulatory agencies to come together.

Ravidasvir plus ritonavir-boosted danoprevir with ribavirin for 12 weeks resulted in 100% sustained virologic response among a cohort of Asian patients with hepatitis C genotype 1 without cirrhosis, according to recently published results of a phase 2 study.

Results of a comparative study of patients with and without diabetes who underwent curative liver resection for hepatitis C-related hepatocellular carcinoma showed that diabetes did not affect surgical outcomes and was not an unfavorable factor in selecting candidates.

Patients who underwent liver transplantation evaluation had a high prevalence of coronary artery disease, especially those with nonalcoholic steatohepatitis-related cirrhosis, hepatitis C-related cirrhosis and alcoholic cirrhosis, according to a recently published study.

The safety and efficacy of Viekirax was comparable between patients with hepatitis C genotype 1b and chronic kidney disease and those without chronic kidney disease, according to a recently published study.

In patients with hepatitis C virus infection who were receiving opioid substitutes, interferon-free drug regimens yielded better outcomes compared with regimens containing interferon, according to researchers.